3种恶性涎腺上皮性肿瘤EGFR和HER-2表达的差异及意义

The difference and clinical significance of the expressions of EGFR and HER-2 in three malignant salivary gland epithelial tumors

目的观察3种恶性涎腺上皮性肿瘤黏液表皮样癌、腺样囊性癌、腺泡细胞癌EGFR和HER-2的表达,分析其表达差异及临床意义。方法应用免疫组化EnVision两步法检测病例组(黏液表皮样癌、腺样囊性癌、腺泡细胞癌)和对照组(良性多形性腺瘤)组织中EGFR和HER-2的表达,应用SPSS 17.0统计软件分析其阳性表达率和表达强度的差异,应用Spearman等级相关分析病例组EGFR和HER-2表达的相关性。结果病例组EGFR阳性表达率和表达强度[71.25%;(+)16例、(++)23例、(+++)18例]均高于对照组[50%;(+)13例、(++)2例],差异有统计学意义(P<0.05,P<0.01)。EGFR在病例组3组间以黏液表皮样癌阳性表达率和表达强度最高(P<0.01)。病例组HER-2的阳性表达率(32.5%)高于对照组(13.33%)(P<0.05)。HER-2在病例组3组间以黏液表皮样癌阳性表达率最高(P<0.05)。EGFR和HER-2在病例组不同性别、年龄、直径、肿瘤分化、组织分型组间比较差异均无统计学意义(P>0.05)。EGFR和HER-2在病例组表达未见相关性(P>0.05)。结论 EGFR在3种恶性涎腺上皮性肿瘤尤其黏液表皮样癌中高频率和高强度表达,可作为分子靶向治疗的潜在靶点。HER-2表达强度较低,其分子靶向治疗意义有待基因水平进一步研究。

Objective To investigate the expressions of EGFR and HER- 2 in mucoepidermoid carcinoma, ade- noid cystic carcinoma and aeinar cell carcinoma, and to analyze the expression difference and clinical significance. Meth- ods The expressions of EGFR and HER - 2 in case group （ mueoepidermoid carcinoma, adenoid cystic carcinoma and acinar cell carcinoma） and control group （benign pleomorphic adenoma） were measured by immunohistochemical method. The difference of expression rate and expression intensity was analyzed by SPSS 17.0 statistical software and correlation be- tween EGFR and HER- 2 in case group was analyzed by Spearman rank correlation. Results The expression rate and expression intensity of EGFR （71.25%, ＋ 16 cases, ＋＋23 cases, ＋＋＋ 18 cases） in case group were significantly higher than control group （50%, ＋ 13, ＋ ＋ 2 ; P 〈0. 05 and P 〈 0. 01 ）. The expression rate and expression intensity of EGFR in mucoepidermoid carcinoma were the highest among three tumors with significant differences （P 〈 0. 01 ）. The positive HER - 2 rate in case group was significantly higher than control group （32. 5% vs. 13.33%, P 〈0. 05）. The positive HER -2 rate in mucoepidermoid carcinoma was the highest among three tmnors with significant differences （P 〈 0. 05）. There was no sig- nificant difference in EGFR or HER - 2 among genders, ages, diameters, tumor differentiation and tissue types （P 〉 0. 05）. The expressions of EGFR and HER - 2 had no correlation in case group （P 〉0. 05）. Conclusion EGFR can be regarded as the potential target of molecular target therapy in three malignant salivary gland epithelial tumors especially in mucoepi- dermoid carcinoma because of its high frequency and intensity expression. The molecular target therapy significance of HER - 2 remains to be further researched on gene level because of its low intensity expression.